Glucose-sensitive albumin-binding derivatives
US-11767332-B2 · Sep 26, 2023 · US
Glucose-sensitive albumin-binding derivatives
US12227528B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12227528-B2 |
| Application number | US-202318210763-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 16, 2023 |
| Priority date | Nov 9, 2017 |
| Publication date | Feb 18, 2025 |
| Grant date | Feb 18, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
First claim
Opening claim text (preview).
The invention claimed is: 1. A diboron compound represented by a structure of R1-X-R2, wherein R1 and R2 are identical, and each has a structure of and wherein X is a linker. 2. The diboron compound of claim 1 , wherein X comprises a carboxylic acid moiety. 3. A diboron conjugate comprising the diboron compound of claim 2 and a drug substance, wherein the diboron compound is conjugated to the drug substance via an optional linker by derivatisation of the carboxylic acid moiety of the diboron compound. 4. The diboron conjugate of claim 3 , wherein the drug substance is an insulin or an insulin analogue.
Assignees
Inventors
Classifications
the modifying agent being an organic compound · CPC title
Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism · CPC title
Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation · CPC title
Total protein determination, e.g. albumin in urine · CPC title
involving blood sugars, e.g. galactose · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12227528B2 cover?
- This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
- Who is the assignee on this patent?
- Novo Nordisk As
- What technology area does this patent fall under?
- Primary CPC classification C07F5/025. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).